Peptide anti-inflammatory mechanisms: BPC-157, GHK-Cu, Thymosin Beta-4 reduce inflammation through specific pathway modulation
In peer-reviewed animal work the concrete numbers are oral doses of roughly 1.442.88 mg/kg given daily to APP/PS1 Alzheimer-model mice over about three months [3] , and low-mg/kg dosing that reversed scopolamine-induced deficits in rodents [1]
The durability of metabolic benefits after washout, the consequences of chronic pan-ERR activation in heart and kidney, and the potential for tolerance or compensatory network changes require longer studies
Hong S-Y, Gil H-W, Yang J-O, et al
Gerade in Deutschland gelten strengere Regelungen als beispielsweise in den USA
BPC-157 is not FDA-approved